Radiopharm extends radioimmunotherapy trial to 5 more cancer types
Radiopharm Theranostics Ltd has received approval to extend its Phase 1 trial of Lu-RAD204 to five more cancer types
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
KNH | Ann: Resignation of Australian Corporate Secretary | 04/03/19 | 0 | 77 | |||
|
|||||||
KNH | Ann: Appendix 4E & Full Year Financial Statements | 28/02/19 | 0 | 58 | |||
|
|||||||
KNH | Ann: CFO Appointment and Cessation | 02/01/19 | 0 | 236 | |||
|
|||||||
KNH | Ann: Interim Financial Report - 30 June 2018 | 30/08/18 | 0 | 144 | |||
|
|||||||
KNH | Ann: Appendix 4D - Half Year 30 June 2018 | 30/08/18 | 0 | 126 | |||
|
|||||||
KNH | Ann: Results of Annual General Meeting | 26/04/18 | 0 | 151 | |||
|
|||||||
KNH | Ann: Notice of Annual General Meeting | 10/04/18 | 0 | 171 | |||
|
|||||||
KNH | Ann: Appendix 4G | 10/04/18 | 0 | 145 | |||
|
See All Discussions